5.4.4.7: hydroperoxy icosatetraenoate isomerase
This is an abbreviated version!
For detailed information about hydroperoxy icosatetraenoate isomerase, go to the full flat file.
Word Map on EC 5.4.4.7
-
5.4.4.7
-
alox12b
-
ichthyosiform
-
lamellar
-
erythroderma
-
cyp4f22
-
abca12
-
nipal4
-
pnpla1
-
harlequin
-
12r-lox
-
collodion
-
lipoxygenase-3
-
12r-lipoxygenase
-
non-bullous
-
cornification
-
ichthyoses
-
epidermis-type
-
hyperkeratosis
-
self-healing
-
galicia
-
hepoxilins
-
epoxyalcohol
-
corneocyte
- 5.4.4.7
- alox12b
-
ichthyosiform
-
lamellar
- erythroderma
-
cyp4f22
-
abca12
-
nipal4
-
pnpla1
- harlequin
- 12r-lox
-
collodion
- lipoxygenase-3
- 12r-lipoxygenase
-
non-bullous
-
cornification
- ichthyoses
-
epidermis-type
-
hyperkeratosis
-
self-healing
-
galicia
-
hepoxilins
-
epoxyalcohol
-
corneocyte
Reaction
Synonyms
ALOXE3, eLOX-3, eLOX3, epidermal lipoxygenase-3, epidermal LOX type 3, hepoxilin synthase
ECTree
Advanced search results
General Information
General Information on EC 5.4.4.7 - hydroperoxy icosatetraenoate isomerase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
malfunction
intra-amniotic delivery of epidermal lipoxygenase-3 (eLOX-3) to mice at gestational day 14.5, both via an adenoviral vector and as recombinant protein, results in fetal growth restriction and intrauterine death. Periodic acid-Schiff staining and RT-PCR analysis of placentae from fetuses exposed to eLOX-3 indicate a lack of glycogen trophoblasts in the junctional zone. Placenta-specific gene expression is altered. Thus, the observed prenatal toxicity of eLOX-3 can be due to a strong effect on placental development. Placentae from eLOX-3-exposed fetuses have an altered structure. Short life-span of eLOX-3 null mice
metabolism
-
eLOX3, is not a functional lipoxygenase enzyme, but has catalytic activity as a hydroperoxide isomerase
physiological function
-
the enzyme participates in the normal process of skin differentiation
physiological function
metabolites of the epidermal lipoxygenase-3 (eLOX-3) are involved in various metabolic pathways. Intra-amniotic delivery of eLOX-3 to mice at gestational day 14.5, both via an adenoviral vector and as recombinant protein, results in fetal growth restriction and intrauterine death. Periodic acid-Schiff staining and RT-PCR analysis of placentae from fetuses exposed to eLOX-3 indicate a lack of glycogen trophoblasts in the junctional zone. Placenta-specific gene expression is altered. Thus, the observed prenatal toxicity of eLOX-3 can be due to a strong effect on placental development. eLOX-3 appears to have some impact on the expression of genes that indirectly influence fetal development